



## Archived Editions (COVID-19 Genomics and Precision Public Health Weekly Update)

Published on 07/08/2021

### COVID-19 Genomics and Precision Public Health Weekly Update Content

- Pathogen and Human Genomics Studies
- Non-Genomics Precision Health Studies
- News, Reviews and Commentaries

#### Pathogen and Human Genomics Studies

- SARS-CoV-2 under an elimination strategy in Hong Kong.

(<https://pubmed.ncbi.nlm.nih.gov/34189537>)

Gu Haogao et al. medRxiv : the preprint server for health sciences 2021 7

By analyzing >1700 genome sequences representing 17% of confirmed cases from 23-January-2020 to 26-January-2021, we reveal the effects of fluctuating control measures on the evolution and epidemiology of SARS-CoV-2 lineages in Hong Kong. Despite numerous importations, only three introductions were responsible for 90% of locally-acquired cases, two of which circulated cryptically for weeks while less stringent measures were in place.

- SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2.

(<https://pubmed.ncbi.nlm.nih.gov/34192529>)

Amanat Fatima et al. Cell 2021 7

Polyclonal antibody responses in vaccinees were robust and comparable to or exceeded those seen after natural infection. However, the ratio of binding to neutralizing antibodies after vaccination was greater than that after natural infection and, at the monoclonal level, we found that the majority of vaccine-induced antibodies did not have neutralizing activity.

- Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2.

(<https://pubmed.ncbi.nlm.nih.gov/34192737>)

Collier Dami A et al. Nature 2021 7

We analysed immune responses following vaccination with mRNA vaccine BNT162b22 in elderly participants and younger health care workers. Serum neutralisation and binding IgG/IgA after the first vaccine dose diminished with increasing age, with a marked drop in participants over 80 years old.

- Ad26.COVS.2 elicited neutralizing activity against Delta and other SARS-CoV-2 variants of concern (<https://www.biorxiv.org/content/10.1101/2021.07.01.450707v1>)

M Jongeneelen et al, BIORXIV, July 1, 2021

Sera from recipients of a single dose of our Ad26.COVS.2 COVID-19 vaccine were tested for neutralizing activity against several SARS-CoV-2 variants of concern. All tested variants demonstrated susceptibility to Ad26.COVS.2-induced serum neutralization albeit mainly reduced as compared to the B.1 strain. Most pronounced reduction was observed for the B.1.351 (Beta; 3.6-fold) and P.1 (Gamma; 3.4-fold) variants that contain similar mutations in the receptor-binding domain (RBD) while only a 1.6-fold reduction was observed for the widely spreading B.1.617.2 (Delta) variant.

- Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants (<https://science.sciencemag.org/content/early/2021/06/30/science.abh1766>)

L Wang et al. Science, July 1, 2021

The emergence of highly transmissible SARS-CoV-2 variants of concern (VOC) that are resistant to therapeutic antibodies highlights the need for continuing discovery of broadly reactive antibodies. We identify four receptor-binding domain targeting antibodies from three early-outbreak convalescent donors with potent neutralizing activity against 23 variants including the B.1.1.7, B.1.351, P.1, B.1.429, B.1.526 and B.1.617 VOCs.

- Combining genomic and epidemiological data to compare the transmissibility of SARS-CoV-2 lineages (<https://www.medrxiv.org/content/10.1101/2021.07.01.21259859v1>)

ME Petrone et al, MEDRXIV, July 2, 2021

We use Connecticut, a state in the northeastern United States in which the SARS-CoV-2 variants B.1.1.7 and B.1.526 co-circulated in early 2021, as a case study for implementing this framework. We find that the  $R_t$  of B.1.1.7 was 6-10% larger than that of B.1.526 in Connecticut in the midst of a COVID-19 vaccination campaign. To assess the generalizability of this framework, we apply it to genomic surveillance data from New York City and observe the same trend.

- An observational cohort study on the incidence of SARS-CoV-2 infection and B.1.1.7 variant infection in healthcare workers by antibody and vaccination status. (<https://pubmed.ncbi.nlm.nih.gov/34216472>)

Lumley Sheila F et al. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2021 7

13,109 HCWs participated; 8285 received the Pfizer-BioNTech vaccine (1407 two doses) and 2738 the Oxford-AstraZeneca vaccine (49 two doses). Compared to unvaccinated seronegative HCWs, natural immunity and two vaccination doses provided similar protection against symptomatic infection: no HCW vaccinated twice had symptomatic infection, and incidence was 98% lower in seropositive HCWs (adjusted incidence rate ratio 0.02 [95%CI <0.01-0.18]). Two vaccine doses or seropositivity reduced the incidence of any PCR-positive result with or without symptoms by 90%

- COVID-19 vaccines dampen genomic diversity of SARS-CoV-2: Unvaccinated patients exhibit more antigenic mutational variance (<https://www.medrxiv.org/content/10.1101/2021.07.01.21259833v1>)

M Niesen et al, MEDRXIV, July 5, 2021

We conducted longitudinal analysis over 1.8 million SARS-CoV-2 genomes from 183 countries or territories to capture vaccination-associated viral evolutionary patterns. To augment this macroscale analysis, we performed viral genome sequencing in 23 vaccine breakthrough COVID-19 patients and 30 unvaccinated COVID-19 patients for whom we also conducted machine-augmented curation of the electronic health records (EHRs). Strikingly, we find the diversity of the SARS-CoV-2 lineages is declining at the country-level with increased rate of mass vaccination.

- Post-vaccination SARS-COV-2 among healthcare workers in New Jersey: a genomic epidemiological study (<https://www.medrxiv.org/content/10.1101/2021.06.30.21259761v1>)  
B Mathema et al, MEDRXIV, July 5, 2021

We describe the early genomic epidemiology of SARS-CoV-2 recovered from vaccinated healthcare professionals (HCP). Our post-vaccination COVID-19 symptoms-based surveillance program among HCPs in a 17-hospital network, identified all vaccinated HCP who tested positive for COVID-19 after routine screening or after self-reporting.

- Mathematical modelling of SARS-CoV-2 variant outbreaks reveals their probability of extinction (<https://www.medrxiv.org/content/10.1101/2021.07.05.21260005v1>)  
H Schioler et al, MEDRXIV, July 6, 2021
- A selective sweep in the Spike gene has driven SARS-CoV-2 human adaptation ([https://www.cell.com/cell/fulltext/S0092-8674\(21\)00833-3?rss=yes&utm\\_source=dlvr.it&utm\\_medium=twitter](https://www.cell.com/cell/fulltext/S0092-8674(21)00833-3?rss=yes&utm_source=dlvr.it&utm_medium=twitter))  
L Kang et al, Cell, July 6, 2021

Over 182,000 SARS-CoV-2 genomes were screened for selective sweep signatures. An adaptive change within the Spike protein receptor-binding domain was identified. This change was predicted and experimentally confirmed to increase affinity to hACE2. As a result, viral replication is enhanced relative to the putative ancestral variant.

- Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants ([https://www.nejm.org/doi/full/10.1056/NEJMc2107799?query=featured\\_home](https://www.nejm.org/doi/full/10.1056/NEJMc2107799?query=featured_home))  
BV Edara et al, NEJM, September 7, 2021

Our results show that the B.1.617.1 variant was 6.8 times less susceptible, and the B.1.617.2 variant was 2.9 times less susceptible, to neutralization by serum from persons who had recovered from Covid-19 and from vaccinated persons than was the WA1/2020 variant. Despite this finding, a majority of the convalescent serum samples (79% [19 of 24 samples] against B.1.617.1 and 96% [23 of 24 samples] against B.1.617.2) and all serum samples from vaccinated persons still had detectable neutralizing activity above the threshold of detection against both variants through 3 months after infection or after the second dose of vaccine.

## Non-Genomics Precision Health Studies

- SARS-CoV-2 under an elimination strategy in Hong Kong.  
(<https://pubmed.ncbi.nlm.nih.gov/34189537>)  
Gu Haogao et al. medRxiv : the preprint server for health sciences 2021 7

By analyzing >1700 genome sequences representing 17% of confirmed cases from 23-January-2020 to 26-January-2021, we reveal the effects of fluctuating control measures on the evolution and epidemiology of SARS-CoV-2 lineages in Hong Kong. Despite numerous importations, only three introductions were responsible for 90% of locally-acquired cases, two of which circulated cryptically for weeks while less stringent measures were in place.

- SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2.

(<https://pubmed.ncbi.nlm.nih.gov/34192529>)

Amanat Fatima et al. Cell 2021 7

Polyclonal antibody responses in vaccinees were robust and comparable to or exceeded those seen after natural infection. However, the ratio of binding to neutralizing antibodies after vaccination was greater than that after natural infection and, at the monoclonal level, we found that the majority of vaccine-induced antibodies did not have neutralizing activity.

- Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2.

(<https://pubmed.ncbi.nlm.nih.gov/34192737>)

Collier Dami A et al. Nature 2021 7

We analysed immune responses following vaccination with mRNA vaccine BNT162b2 in elderly participants and younger health care workers. Serum neutralisation and binding IgG/IgA after the first vaccine dose diminished with increasing age, with a marked drop in participants over 80 years old.

- Ad26.COVS elicited neutralizing activity against Delta and other SARS-CoV-2 variants of concern

(<https://www.biorxiv.org/content/10.1101/2021.07.01.450707v1>)

M Jongeneelen et al, BIORXIV, July 1, 2021

Sera from recipients of a single dose of our Ad26.COVS COVID-19 vaccine were tested for neutralizing activity against several SARS-CoV-2 variants of concern. All tested variants demonstrated susceptibility to Ad26.COVS-induced serum neutralization albeit mainly reduced as compared to the B.1 strain. Most pronounced reduction was observed for the B.1.351 (Beta; 3.6-fold) and P.1 (Gamma; 3.4-fold) variants that contain similar mutations in the receptor-binding domain (RBD) while only a 1.6-fold reduction was observed for the widely spreading B.1.617.2 (Delta) variant.

- Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants

(<https://science.sciencemag.org/content/early/2021/06/30/science.abh1766>)

L Wang et al. Science, July 1, 2021

The emergence of highly transmissible SARS-CoV-2 variants of concern (VOC) that are resistant to therapeutic antibodies highlights the need for continuing discovery of broadly reactive antibodies. We identify four receptor-binding domain targeting antibodies from three early-outbreak convalescent donors with potent neutralizing activity against 23 variants including the B.1.1.7, B.1.351, P.1, B.1.429, B.1.526 and B.1.617 VOCs.

- Combining genomic and epidemiological data to compare the transmissibility of SARS-CoV-2 lineages

(<https://www.medrxiv.org/content/10.1101/2021.07.01.21259859v1>)

ME Petrone et al, MEDRXIV, July 2, 2021

We use Connecticut, a state in the northeastern United States in which the SARS-CoV-2 variants B.1.1.7 and B.1.526 co-circulated in early 2021, as a case study for implementing this framework. We find that the  $R_t$  of B.1.1.7 was 6-10% larger than that of B.1.526 in Connecticut in the midst of a COVID-19 vaccination campaign. To assess the generalizability of this framework, we apply it to genomic surveillance data from New York City and observe the same trend.

- An observational cohort study on the incidence of SARS-CoV-2 infection and B.1.1.7 variant infection in healthcare workers by antibody and vaccination status.

(<https://pubmed.ncbi.nlm.nih.gov/34216472>)

Lumley Sheila F et al. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2021 7

13,109 HCWs participated; 8285 received the Pfizer-BioNTech vaccine (1407 two doses) and 2738 the Oxford-AstraZeneca vaccine (49 two doses). Compared to unvaccinated seronegative HCWs, natural immunity and two vaccination doses provided similar protection against symptomatic infection: no HCW vaccinated twice had symptomatic infection, and incidence was 98% lower in seropositive HCWs (adjusted incidence rate ratio 0.02 [95%CI <0.01-0.18]). Two vaccine doses or seropositivity reduced the incidence of any PCR-positive result with or without symptoms by 90%

- COVID-19 vaccines dampen genomic diversity of SARS-CoV-2: Unvaccinated patients exhibit more antigenic mutational variance (<https://www.medrxiv.org/content/10.1101/2021.07.01.21259833v1>)  
M Niesen et al, MEDRXIV, July 5, 2021

We conducted longitudinal analysis over 1.8 million SARS-CoV-2 genomes from 183 countries or territories to capture vaccination-associated viral evolutionary patterns. To augment this macroscale analysis, we performed viral genome sequencing in 23 vaccine breakthrough COVID-19 patients and 30 unvaccinated COVID-19 patients for whom we also conducted machine-augmented curation of the electronic health records (EHRs). Strikingly, we find the diversity of the SARS-CoV-2 lineages is declining at the country-level with increased rate of mass vaccination.

- Post-vaccination SARS-COV-2 among healthcare workers in New Jersey: a genomic epidemiological study (<https://www.medrxiv.org/content/10.1101/2021.06.30.21259761v1>)  
B Mathema et al, MEDRXIV, July 5, 2021

We describe the early genomic epidemiology of SARS-CoV-2 recovered from vaccinated healthcare professionals (HCP). Our post-vaccination COVID-19 symptoms-based surveillance program among HCPs in a 17-hospital network, identified all vaccinated HCP who tested positive for COVID-19 after routine screening or after self-reporting.

- Mathematical modelling of SARS-CoV-2 variant outbreaks reveals their probability of extinction (<https://www.medrxiv.org/content/10.1101/2021.07.05.21260005v1>)  
H Schioler et al, MEDRXIV, July 6, 2021

- A selective sweep in the Spike gene has driven SARS-CoV-2 human adaptation ([https://www.cell.com/cell/fulltext/S0092-8674\(21\)00833-3?rss=yes&utm\\_source=dlvr.it&utm\\_medium=twitter](https://www.cell.com/cell/fulltext/S0092-8674(21)00833-3?rss=yes&utm_source=dlvr.it&utm_medium=twitter))  
L Kang et al, Cell, July 6, 2021

Over 182,000 SARS-CoV-2 genomes were screened for selective sweep signatures. An adaptive change within the Spike protein receptor-binding domain was identified. This change was predicted and experimentally confirmed to increase affinity to hACE2. As a result, viral replication is enhanced relative to the putative ancestral variant.

- Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants ([https://www.nejm.org/doi/full/10.1056/NEJMc2107799?query=featured\\_home](https://www.nejm.org/doi/full/10.1056/NEJMc2107799?query=featured_home))

BV Edara et al, NEJM, September 7, 2021

Our results show that the B.1.617.1 variant was 6.8 times less susceptible, and the B.1.617.2 variant was 2.9 times less susceptible, to neutralization by serum from persons who had recovered from Covid-19 and from vaccinated persons than was the WA1/2020 variant. Despite this finding, a majority of the convalescent serum samples (79% [19 of 24 samples] against B.1.617.1 and 96% [23 of 24 samples] against B.1.617.2) and all serum samples from vaccinated persons still had detectable neutralizing activity above the threshold of detection against both variants through 3 months after infection or after the second dose of vaccine.

## News, Reviews and Commentaries

- SARS-CoV-2 under an elimination strategy in Hong Kong.

(<https://pubmed.ncbi.nlm.nih.gov/34189537>)

Gu Haogao et al. medRxiv : the preprint server for health sciences 2021 7

By analyzing >1700 genome sequences representing 17% of confirmed cases from 23-January-2020 to 26-January-2021, we reveal the effects of fluctuating control measures on the evolution and epidemiology of SARS-CoV-2 lineages in Hong Kong. Despite numerous importations, only three introductions were responsible for 90% of locally-acquired cases, two of which circulated cryptically for weeks while less stringent measures were in place.

- SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2.

(<https://pubmed.ncbi.nlm.nih.gov/34192529>)

Amanat Fatima et al. Cell 2021 7

Polyclonal antibody responses in vaccinees were robust and comparable to or exceeded those seen after natural infection. However, the ratio of binding to neutralizing antibodies after vaccination was greater than that after natural infection and, at the monoclonal level, we found that the majority of vaccine-induced antibodies did not have neutralizing activity.

- Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2.

(<https://pubmed.ncbi.nlm.nih.gov/34192737>)

Collier Dami A et al. Nature 2021 7

We analysed immune responses following vaccination with mRNA vaccine BNT162b2 in elderly participants and younger health care workers. Serum neutralisation and binding IgG/IgA after the first vaccine dose diminished with increasing age, with a marked drop in participants over 80 years old.

- Ad26.COVS.2 elicited neutralizing activity against Delta and other SARS-CoV-2 variants of concern (<https://www.biorxiv.org/content/10.1101/2021.07.01.450707v1>)

M Jongeneelen et al, BIORXIV, July 1, 2021

Sera from recipients of a single dose of our Ad26.COVS.2 COVID-19 vaccine were tested for neutralizing activity against several SARS-CoV-2 variants of concern. All tested variants demonstrated susceptibility to Ad26.COVS.2-induced serum neutralization albeit mainly reduced as compared to the B.1 strain. Most pronounced reduction was observed for the B.1.351 (Beta; 3.6-fold) and P.1 (Gamma; 3.4-fold) variants that contain similar mutations in the receptor-binding domain (RBD) while only a 1.6-fold reduction was observed for the widely spreading B.1.617.2 (Delta) variant.

- Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants (<https://science.sciencemag.org/content/early/2021/06/30/science.abh1766>)

L Wang et al. Science, July 1, 2021

The emergence of highly transmissible SARS-CoV-2 variants of concern (VOC) that are resistant to therapeutic antibodies highlights the need for continuing discovery of broadly reactive antibodies. We identify four receptor-binding domain targeting antibodies from three early-outbreak convalescent donors with potent neutralizing activity against 23 variants including the B.1.1.7, B.1.351, P.1, B.1.429, B.1.526 and B.1.617 VOCs.

- Combining genomic and epidemiological data to compare the transmissibility of SARS-CoV-2 lineages (<https://www.medrxiv.org/content/10.1101/2021.07.01.21259859v1>)

ME Petrone et al, MEDRXIV, July 2, 2021

We use Connecticut, a state in the northeastern United States in which the SARS-CoV-2 variants B.1.1.7 and B.1.526 co-circulated in early 2021, as a case study for implementing this framework. We find that the  $R_t$  of B.1.1.7 was 6-10% larger than that of B.1.526 in Connecticut in the midst of a COVID-19 vaccination campaign. To assess the generalizability of this framework, we apply it to genomic surveillance data from New York City and observe the same trend.

- An observational cohort study on the incidence of SARS-CoV-2 infection and B.1.1.7 variant infection in healthcare workers by antibody and vaccination status. (<https://pubmed.ncbi.nlm.nih.gov/34216472>)

Lumley Sheila F et al. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2021 7

13,109 HCWs participated; 8285 received the Pfizer-BioNTech vaccine (1407 two doses) and 2738 the Oxford-AstraZeneca vaccine (49 two doses). Compared to unvaccinated seronegative HCWs, natural immunity and two vaccination doses provided similar protection against symptomatic infection: no HCW vaccinated twice had symptomatic infection, and incidence was 98% lower in seropositive HCWs (adjusted incidence rate ratio 0.02 [95%CI <0.01-0.18]). Two vaccine doses or seropositivity reduced the incidence of any PCR-positive result with or without symptoms by 90%

- COVID-19 vaccines dampen genomic diversity of SARS-CoV-2: Unvaccinated patients exhibit more antigenic mutational variance (<https://www.medrxiv.org/content/10.1101/2021.07.01.21259833v1>)

M Niesen et al, MEDRXIV, July 5, 2021

We conducted longitudinal analysis over 1.8 million SARS-CoV-2 genomes from 183 countries or territories to capture vaccination-associated viral evolutionary patterns. To augment this macroscale analysis, we performed viral genome sequencing in 23 vaccine breakthrough COVID-19 patients and 30 unvaccinated COVID-19 patients for whom we also conducted machine-augmented curation of the electronic health records (EHRs). Strikingly, we find the diversity of the SARS-CoV-2 lineages is declining at the country-level with increased rate of mass vaccination.

- Post-vaccination SARS-COV-2 among healthcare workers in New Jersey: a genomic epidemiological study (<https://www.medrxiv.org/content/10.1101/2021.06.30.21259761v1>)  
B Mathema et al, MEDRXIV, July 5, 2021

We describe the early genomic epidemiology of SARS-CoV-2 recovered from vaccinated healthcare professionals (HCP). Our post-vaccination COVID-19 symptoms-based surveillance program among HCPs in a 17-hospital network, identified all vaccinated HCP who tested positive for COVID-19 after routine screening or after self-reporting.

- Mathematical modelling of SARS-CoV-2 variant outbreaks reveals their probability of extinction (<https://www.medrxiv.org/content/10.1101/2021.07.05.21260005v1>)  
H Schioler et al, MEDRXIV, July 6, 2021

- A selective sweep in the Spike gene has driven SARS-CoV-2 human adaptation ([https://www.cell.com/cell/fulltext/S0092-8674\(21\)00833-3?rss=yes&utm\\_source=dlvr.it&utm\\_medium=twitter](https://www.cell.com/cell/fulltext/S0092-8674(21)00833-3?rss=yes&utm_source=dlvr.it&utm_medium=twitter))  
L Kang et al, Cell, July 6, 2021

Over 182,000 SARS-CoV-2 genomes were screened for selective sweep signatures. An adaptive change within the Spike protein receptor-binding domain was identified. This change was predicted and experimentally confirmed to increase affinity to hACE2. As a result, viral replication is enhanced relative to the putative ancestral variant.

- Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants ([https://www.nejm.org/doi/full/10.1056/NEJMc2107799?query=featured\\_home](https://www.nejm.org/doi/full/10.1056/NEJMc2107799?query=featured_home))  
BV Edara et al, NEJM, September 7, 2021

Our results show that the B.1.617.1 variant was 6.8 times less susceptible, and the B.1.617.2 variant was 2.9 times less susceptible, to neutralization by serum from persons who had recovered from Covid-19 and from vaccinated persons than was the WA1/2020 variant. Despite this finding, a majority of the convalescent serum samples (79% [19 of 24 samples] against B.1.617.1 and 96% [23 of 24 samples] against B.1.617.2) and all serum samples from vaccinated persons still had detectable neutralizing activity above the threshold of detection against both variants through 3 months after infection or after the second dose of vaccine.

**Disclaimer:** Articles listed in COVID-19 Genomics and Precision Public Health Weekly Update are selected by the CDC Office of Public Health Genomics to provide current awareness of the scientific literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the Clips, or persons quoted therein, are strictly their

*own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.*

---

Page last reviewed: Oct 1, 2020

Page last updated: Jul 09, 2021

Content source: Office of Genomics and Precision Public Health (<http://www.cdc.gov/genomics/>), CDC Office of Science (<https://www.cdc.gov/od/science/index.htm>)